Comment
Author: Admin | 2025-04-28
Are available on the effect of rifampin on linezolid levels (Blassman 2016; Gómez 2011; Hoyo 2012).Cystic fibrosis, acute pulmonary exacerbation, moderate to severe (off-label use): Empiric therapy or pathogen-directed therapy for methicillin-resistant S. aureus (MRSA) (Chmiel 2014; Simon 2019).Oral, IV: 600 mg every 12 hours (Chmiel 2014; Keel 2011). Duration is usually 10 days to 3 weeks or longer based on clinical response (Flume 2009; Simon 2019).Diabetic foot infection, moderate to severe: Empiric therapy or pathogen-directed therapy for MRSA.Oral, IV: 600 mg every 12 hours; for empiric therapy, use as part of an appropriate combination regimen. Duration is usually 2 to 4 weeks in the absence of osteomyelitis; prolonged use of linezolid may be limited by toxicity (IDSA [Lipsky 2012]; Lipsky 2004; Weintrob 2019).Endocarditis, treatment, native or prosthetic valve (off-label use): Pathogen-directed therapy for penicillin-, aminoglycoside-, and vancomycin-resistant enterococci.IV, Oral: 600 mg every 12 hours for >6 weeks; prolonged use of linezolid may be limited by toxicity (AHA [Baddour 2015]).Intracranial abscess (brain abscess, intracranial epidural abscess) and spinal epidural abscess (alternative agent) (off-label use): Pathogen-directed therapy for MRSA.IV, Oral: 600 mg every 12 hours; duration generally ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess, and 6 to 8 weeks for intracranial epidural abscess; prolonged use of linezolid may be limited by toxicity (Bodilsen 2018; IDSA [Liu 2011]; Ntziora 2007; Sexton 2019a; Sexton 2019b; Southwick 2019).Meningitis, bacterial (off-label use): As pathogen-directed therapy (eg, penicillin-, ampicillin-, and vancomycin-resistant enterococci; Staphylococcus spp., including MRSA [alternative agent]; C. acnes [alternative agent]).IV: 600 mg every 12 hours. Treatment duration is usually 10 to 14 days (IDSA [Tunkel 2004]; IDSA [Tunkel 2017]; Ntziora 2007; Sipahi 2013).Osteomyelitis and/or discitis (alternative agent) (off-label use):Pathogen-directed therapy for Staphylococcus spp., including methicillin-resistant S. aureus: Oral, IV: 600 mg every 12 hours (Birmingham 2003; IDSA [Berbari
Add Comment